Skip to main content
SpringerLink
Log in

Silymarin and Its Role in Chronic Diseases

  • Chapter
  • First Online:
Drug Discovery from Mother Nature

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 929))

Abstract

Silymarin is the active constituent of Silybum marianum (milk thistle) which is a C-25 containing flavonolignan. Milk thistle has a lot of traditional values, being used as a vegetable, as salad, as bitter tonic, and as galactogogue in nursing mothers and in various ailments such as liver complications, depression, dyspepsia, spleenic congestions, varicose veins, diabetes, amenorrhea, uterine hemorrhage, and menstrual problems. In this present chapter, a comprehensive attempt has been made to discuss the potential of silymarin in chronic disorders. An insight into modulation of cellular signaling by silymarin and its implication in various disorders such as liver disorders, inflammatory disorders, cancer, neurological disorders, skin diseases, and hypercholesterolemia is being provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Ind J Med Res 124:491–504

    CAS  Google Scholar 

  2. Luper S (1998) A review of plants used in the treatment of liver diseases: Part 1. Altern Med Rev 3:410–421

    CAS  PubMed  Google Scholar 

  3. Pepping J (1999) Milk thistle: Silybum marianum. Am J Health Syst Pharm 56:1195–1197

    CAS  PubMed  Google Scholar 

  4. Barceloux DG (2008) Medical toxicology of natural substances. Wiley, New Jersey

    Book  Google Scholar 

  5. Hackett ES, Twedt DC, Gustafson DL (2013) Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med 27:10–16

    Article  CAS  PubMed  Google Scholar 

  6. Morazzoni P, Montalbetti A, Malandrino S et al (1993) Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18:289–297

    Article  CAS  PubMed  Google Scholar 

  7. Ruzickowa G, Fojlova J, Souckova M (2011) Silybum marianum (L.) Gaertn. Seed oil from the perspective of environment and genotype- a pilot study. Acta Fytotechnica Zootechnica 14:9–12

    Google Scholar 

  8. Goli SAH, Kadivar M, Bahrami B, Sabzalian MR (2008) Physical and chemical characteristics of Silybum marianum seed oil. Iran J Food Sci Technol 4:27–32

    Google Scholar 

  9. Khan I, Khattak HU, Ullah I, Bangash FK (2007) Study of physicochemical properties of Silybum marianum seed oil. J Chem Soc Pak 29:545–548

    CAS  Google Scholar 

  10. Pliskova M, Vondracek J, Kren V et al (2005) Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 215:80–89

    Article  CAS  PubMed  Google Scholar 

  11. Zhu W, Zhang JS, Young YF (2001) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22:1399–1403

    Article  CAS  PubMed  Google Scholar 

  12. Krena V, Walterov D (2005) Silybin and silymarin—new effects and applications. Biomed Papers 149:29–41

    Article  Google Scholar 

  13. Zhang SH, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–1267

    Article  CAS  PubMed  Google Scholar 

  14. Zhang SZ, Morris ME (2003) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20:1184–1191

    Article  CAS  PubMed  Google Scholar 

  15. Nguyen H, Zhang SZ, Morris ME (2002) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250–257

    Article  Google Scholar 

  16. Maser P, Vogel D, Schmid C et al (2001) Identification and characterization of trypanocides by functional expression of an adenosine transporter from Trypanosoma brucei in yeast. J Mol Med 79:121–127

    Article  CAS  PubMed  Google Scholar 

  17. Saliou C, Valacchi G, Rimbach G (2001) Assessing bioflavonoids as regulators of NF-κB activity and inflammatory gene expression in mammalian cells. Meth Enzymol 335:380–386

    Article  CAS  PubMed  Google Scholar 

  18. Morishima C, Polyak SJ, Lohmann V et al (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107:5995–5999

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yoo HG, Jung SN, Hwang YS et al (2004) Involvement of NF-κB and caspases in silibinin-induced apoptosis of endothelial cells. Int J Mol Med 13:81–86

    CAS  PubMed  Google Scholar 

  20. Sinnberg T, Menzel M, Kaesler S et al (2010) Suppression of casein kinase 1alpha in melanoma cells induces a switch in betacatenin signaling to promote metastasis. Cancer Res 70:6999–7009

    Article  CAS  PubMed  Google Scholar 

  21. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398

    Article  CAS  PubMed  Google Scholar 

  22. Liu C, Li Y, Semenov M et al (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837–847

    Article  CAS  PubMed  Google Scholar 

  23. Hart M, Concordet JP, Lassot I et al (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210

    Article  CAS  PubMed  Google Scholar 

  24. Tyagi A, Agarwal C, Agarwal R (2002) Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther 1:525–532

    CAS  PubMed  Google Scholar 

  25. Agarwal R (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60:1051–1059

    Article  CAS  PubMed  Google Scholar 

  26. Wang JY, Chang CC, Chiang CC et al (2012) Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 113:1733–1743

    CAS  PubMed  Google Scholar 

  27. Singh RP, Agarwal R (2004) Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 4:1–11

    Article  CAS  PubMed  Google Scholar 

  28. Pferschy-Wenzig EM, Atanasov AG, Malainer C et al (2014) Identification of Isosilybin A from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J Nat Prod 77:842–847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Prakash P, Singh V, Jain M et al (2014) Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. Eur J Pharmacol 727:15–28

    Article  CAS  PubMed  Google Scholar 

  30. Demirci B, Demir O, Dost T et al (2013) Treated effect of silymarin on vascular function of aged rats: dependant on nitric oxide pathway. Pharm Biol [Epub ahead of print]

    Google Scholar 

  31. Zhao F, Shi D, Li T et al (2015) Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro. Clin Exp Pharmacol Physiol. doi:10.1111/1440-1681.12448. [Epub ahead of print]

    Google Scholar 

  32. Ferenci P, Dragosics B, Dittrich H et al (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9:105–113

    Article  CAS  PubMed  Google Scholar 

  33. Muriel P, Mourelle M (1990) Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 10:275–279

    Article  CAS  PubMed  Google Scholar 

  34. Mayer KE, Myers RP, Lee SS (2005) Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepatitis 12:559–567

    Article  CAS  Google Scholar 

  35. Vargas-Mendoza N, Madrigal-Santillan E, Morales-Gonzalez A et al (2014) Hepatoprotective effect of silymarin. World J Hepatol 6:144–149

    Article  PubMed  PubMed Central  Google Scholar 

  36. Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 17:2288–2301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dixit N, Baboota S, Kohli K et al (2009) Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Ind J Pharmacol 39:172–179

    Article  Google Scholar 

  38. Dehmlow C, Erhard J, De Groot H (1996) Inhibition of kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749–754

    Article  CAS  PubMed  Google Scholar 

  39. Dehmlow C, Murawski N, De Groot H (1996) Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 58:1591–1600

    Article  CAS  PubMed  Google Scholar 

  40. Manna SK, Mukhopadhyay A, Van NT et al (1999) Silymarin suppresses TNF-induced activation of NF-kB, c-Jun N-terminal kinase and apoptosis. J Immunol 163:6800–6809

    CAS  PubMed  Google Scholar 

  41. Haddad Y, Vallerand D, Brault A et al (2011) Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Altern Med 1–10

    Google Scholar 

  42. Colturato CP, Constantin RP, Maeda AS Jr et al (2012) Chem Biol Interact 195:119–132

    Article  CAS  PubMed  Google Scholar 

  43. DerMarderosian A (2001) The reviews of natural products, 1st edn. Facts and Comparisons, St. Louis

    Google Scholar 

  44. Meeran SM, Katiyar S, Elmets CA et al (2006) Silymarin inhibits UV radiation induced immunosuppression through augmentation of interleukin-12 in mice. Mol Cancer Ther 7:1660–1668

    Article  Google Scholar 

  45. Strazzabosco M (1999) Effects of silybinin on biliary lipid composition. J Hepatol 12:290–292

    Google Scholar 

  46. Bhattacharya S (2011) Milk thistle (Silybum marianum L. Gaert.) seeds in health. In: Preedy VR, Watson RR, Patel V (eds) Nuts and seeds in health and disease prevention, 1st edn. Academic Press (an imprint of Elsevier), London, Burlington, San Diego

    Google Scholar 

  47. Kshirsagar A, Ingawale D, Ashok P et al (2009) Silymarin: a comprehensive review. Pharmacognosy Rev 3:116–124

    CAS  Google Scholar 

  48. Kreeman V, Skottova N, Walterova D (1998) Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 64:138–142

    Article  Google Scholar 

  49. Gazak R, Walterova D, Kren V (2007) Silybin and silymarin—new and emerging applications in medicine. Curr Med Chem 14:315–338

    Article  CAS  PubMed  Google Scholar 

  50. Tyagi A, Agarwal C, Harrison G et al (2004) Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 25:1711–1720

    Article  CAS  PubMed  Google Scholar 

  51. Das S, Roy P, Auddy RG et al (2011) Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity. Int J Nanomed 6:1291–1301

    Article  CAS  Google Scholar 

  52. Jain A, Yadav A, Bozhkov AI et al (2011) Therapeutic efficacy of sylimarin and naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicol Environ Saf 74:607–614

    Article  CAS  PubMed  Google Scholar 

  53. Mohamed O, Salam EA, Saleem AA et al (2010) Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology 18:87–94

    Article  Google Scholar 

  54. Shaker E, Mahmoud H, Mnaa S (2010) Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol 48:803–806

    Article  CAS  PubMed  Google Scholar 

  55. Das SK, Vasudevan DM. Protective effects of silymarin, a milk thistle (Silybum marianum) derivative on ethanol induced oxidative stress in liver. Indian J Biochem Biophys 43:306–311

    Google Scholar 

  56. Zhang W, Hong R, Tian T (2013) Silymarin’s protective effects and possible mechanisms on alcoholic fatty liver for rats. Biomol Ther (Seoul) 30:264–269

    Article  Google Scholar 

  57. Ramakrishnan G, Lo Muzio L, Elinos-Baez CM et al (2009) Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 42:229–240

    Article  CAS  PubMed  Google Scholar 

  58. Varghese L, Agarwal C, Tyagi A et al (2005) Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 11:8441–8448

    Article  CAS  PubMed  Google Scholar 

  59. Bhatia N, Zhao J, Wolf DM et al (1999) Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 147:77–84

    Article  CAS  PubMed  Google Scholar 

  60. Huang Q, Wu LJ, Tashiro S et al (2005) Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. J Asian Nat Prod Res 7:701–709

    Article  CAS  PubMed  Google Scholar 

  61. Sharma Y, Agarwal C, Singh AK et al (2001) Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 30:224–236

    Article  CAS  PubMed  Google Scholar 

  62. Katiyar SK, Korman NJ, Mukhtar H et al (1997) Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 89:556–566

    Article  CAS  PubMed  Google Scholar 

  63. Das SK, Mukherjee S, Vasudevan DM (2008) Medicinal properties of milk thistle with special reference to silymarin: an overview. Nat Prod Radiance 7:182–192

    Google Scholar 

  64. Chen PN, Hsieh YS, Chiou HL et al. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 156:141–150

    Google Scholar 

  65. Wang MJ, Lin WW, Chen HL et al (2002) Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 16:2103–2112

    Article  PubMed  Google Scholar 

  66. Sayyah M, Boostani H, Pakseresht S et al (2010) Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. PNBP 34:362–365

    CAS  Google Scholar 

  67. Chlopeikova A, Psotova J, Miketova P et al (2004) Chemopreventive effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytotherapy Res 18:107–110

    Article  Google Scholar 

  68. Zholobenko A, Modriansky M (2014) Silymarin and its constituents in cardiac preconditioning. Fitoterapia 97:122–132

    Article  CAS  PubMed  Google Scholar 

  69. Vereckei AS, Blazovics A, Gyorgy I et al (1993) The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 4:161–177

    Article  CAS  PubMed  Google Scholar 

  70. Breschi MC, Martinotti E, Apostoliti F et al (2002) Protective effect of silymarin in antigen challenge- and histamin-induced bronchoconstriction in vivo guinea-pigs. Eur J Pharmacol 437:91–95

    Article  CAS  PubMed  Google Scholar 

  71. Soto C, Mena R, Luna J et al (2004) Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 75:2167–2180

    Article  CAS  PubMed  Google Scholar 

  72. Kock HP, Bachner J, Loffler E (1985) Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Meth Find Exp Clin Pharmacol 7:409–413

    Google Scholar 

  73. Khan AQ, Khan R, Tahir M et al (2014) Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: possible role of oxidative stress and inflammation. Nutr Cancer 66:249–258

    Article  CAS  PubMed  Google Scholar 

  74. Katiyar SK (2002) Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 21:1213–1222

    CAS  PubMed  Google Scholar 

  75. Soto C, Perez J, Garcia V et al (2010) Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine 17:1090–1094

    Article  CAS  PubMed  Google Scholar 

  76. Kaur G, Athar M, Alam MS (2010) Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs 28:703–713

    Article  CAS  PubMed  Google Scholar 

  77. Nazemian F, Karimi GH, Moatamedi M et al (2010) Effect of Silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytotherapy Res 24:1654–1657

    Article  CAS  Google Scholar 

  78. Polyak SJ, Morishima C, Shuhart MC et al (2007) Inhibition of T-cell inflammatory cytokines, hepatocyte NF-Kappa B signaling and HCV infection by standardised silymarin. Gastroenterology 132:1925–1936

    Article  CAS  PubMed  Google Scholar 

  79. Al-Rasheed NM, Al-Rasheed NM, Faddah LM et al (2014) Potential impact of silymarin in combination with chlorogenic acid and/or melatonin in combating cardiomyopathy induced by carbon tetrachloride. Saudi J Biol Sci 21:265–274

    Article  CAS  PubMed  Google Scholar 

  80. Nabila EA, Hania NC, Noura SAZ et al (2010) Protective effect of silymarin on cisplatin-induced nephrotoxicity in rats. Pak J Nutr 9:624–636

    Article  Google Scholar 

  81. Shahbazi F, Dashti-Khavidaki S, Khalili H et al (2012) Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J Pharm Pharm Sci 15:112–123

    Article  CAS  PubMed  Google Scholar 

  82. Laekeman G, De Coster S, De Meyer K (2003) St. Mary’s thistle: an overview. J Pharm Belg 58:28–31

    CAS  PubMed  Google Scholar 

  83. Muriel P, Garciapina T, Perez-Alvarez V et al (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12:439–442

    Article  CAS  PubMed  Google Scholar 

  84. Boigk G, Stroedter L, Herbst H et al (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649

    Article  CAS  PubMed  Google Scholar 

  85. Skottova N, Krecman V (1998) Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palackianae Olomucensis Facultatitis Med 141:39–40

    CAS  Google Scholar 

  86. Neha, Kumar A, Jaggi AS et al (2014) Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia. Naunyn Schmiedebergs Arch Pharmacol 387:777–787

    Article  CAS  PubMed  Google Scholar 

  87. Soto CP, Perez BL, Favari LP et al (1998) Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Pharmacol Toxicol 119:125–129

    CAS  Google Scholar 

  88. Cheng KC, Asakawa A, Li YX et al (2014) Silymarin induces insulin resistance through an increase of phosphatase and tensin homolog in wistar rats. PLOS ONE

    Google Scholar 

  89. Zi X, Mukhtar H, Agarwal R (1997) Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 239:334–339

    Article  CAS  PubMed  Google Scholar 

  90. De La Lastra CA, Martin MJ, Motilva V et al (1995) Gastroprotection induced by silymarin, the hepatoprotective principle of Silybum marianum in ischemia-reperfusion mucosal injury: role of neutrophils. Planta Med 61:116–119

    Article  Google Scholar 

  91. Albrecht M (1992) Therapy of toxic liver pathologies with Legalon. Z Klin Med 47:87–92

    Google Scholar 

  92. Salhanick SD, Wax PM, Schneider SM, Tong TC et al (2008) Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model. Ann Emerg Med 52:184–185

    Article  PubMed  Google Scholar 

  93. Feher J, Deak G, Muzes G et al (1989) Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 130:2723–2727

    CAS  PubMed  Google Scholar 

  94. Moscarella S, Giusit A, Marra F et al (1993) Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease. Curr Ther Res 53:98–102

    Article  Google Scholar 

  95. Magliulo E, Gagliardi B, Fiori GP (1978) Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin 73:1060–1065

    CAS  PubMed  Google Scholar 

  96. Nassuato G, Iemmolo RM, Strazzabosco M et al (1991) Effect of Silibinin on biliary lipid composition experimental and clinical study. J Hepatol 12:290–295

    Article  CAS  PubMed  Google Scholar 

  97. Velussi M, Cernigoi AM, De Monte A et al (1997) Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26:871–879

    Article  CAS  PubMed  Google Scholar 

  98. Lang I, Nekam K, Gonzalez-Cabello R et al (1990) Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med 15:123–127

    CAS  PubMed  Google Scholar 

  99. Grossmann M, Hoermann R, Weiss M et al (1995) Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol 90:1500–1503

    CAS  PubMed  Google Scholar 

  100. Feher J, Lang I, Nekam K et al (1990) In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med 15:129–134

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacology Division, Department of Pharmaceutical Sciences and Drug Research, Faculty of Medicine, Punjabi University, Patiala, 147002, Punjab, India

    Neha, Amteshwar S. Jaggi & Nirmal Singh

Authors
  1. Neha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amteshwar S. Jaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nirmal Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nirmal Singh .

Editor information

Editors and Affiliations

  1. Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Subash Chandra Gupta

  2. MD Anderson Cancer Center, University of Texas, Houston, Texas, USA

    Sahdeo Prasad

  3. Inflammation Research Institute, San Diego, California, USA

    Bharat B. Aggarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Neha, Jaggi, A.S., Singh, N. (2016). Silymarin and Its Role in Chronic Diseases. In: Gupta, S., Prasad, S., Aggarwal, B. (eds) Drug Discovery from Mother Nature. Advances in Experimental Medicine and Biology, vol 929. Springer, Cham. https://doi.org/10.1007/978-3-319-41342-6_2

Download citation

Publish with us

Policies and ethics

Search

Navigation